The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Martin SjöströmShuang G ZhaoSamuel LevyMeng ZhangYuhong NingRaunak ShresthaArian LundbergCameron HerbertsAdam FoyeRahul R AggarwalJunjie T HuaHaolong LiAnna BergamaschiCorinne Maurice-DrorAshutosh MaheshwariSujun ChenSarah W S NgMichael FraserJessica PetriccaMichael FraserLisa ChesnerMarc D PerryThaidy Moreno-RodriguezWilliam S ChenJoshi J AlumkalJonathan ChouAlicia K MorgansTomasz M BeerGeorge V ThomasMartin GleavePaul LloydTierney PhillipsErin McCarthyMichael C HaffnerAmina ZoubeidiMatti AnnalaRobert E ReiterMatthew B RettigOwen N WitteLawrence FongRohit BoseFranklin W HuangJoshua M LangAnders BjartellNupam P MahajanPrimo N LaraChristopher P EvansPhuoc T TranEdwin M PosadasChuan HeXiao-Long CuiJiaoti HuangWilbert ZwartLuke A GilbertChristopher A MaherPaul C BoutrosKim N ChiAlan AshworthEric J SmallHousheng Hansen HeAlexander W WyattDavid A QuigleyFelix Y FengPublished in: Cancer research (2022)
In prostate cancer, 5-hydroxymethylcytosine delineates oncogene activation and stage-specific cell states and can be analyzed in liquid biopsies to detect cancer phenotypes. See related article by Wu and Attard, p. 3880.